TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19766350

Group type: EXPERIMENTAL
Intervention: PUVA
Number of subjects: 40

Group type: COMPARATOR
Intervention: UVA plus placebo
Number of subjects: 40
Study: 17192500

Group type: COMPARATOR
Intervention: 15-mg pioglitazone/500-mg metformin fixed-dose combination tablets
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: 15-mg pioglitazone/500-mg metformin coadministration of commercial tablets
Number of subjects: 124

Group type: COMPARATOR
Intervention: 15-mg pioglitazone/850-mg metformin fixed-dose combination tablets
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: 15-mg pioglitazone/850-mg metformin coadministration of commercial tablets
Number of subjects: 124
Study: 15358467

Group type: EXPERIMENTAL
Intervention: Mifepristone 75 mg in capsule form followed by misoprostol 600 microg
Number of subjects: 480

Group type: COMPARATOR
Intervention: Mifepristone 150 mg in tablet form followed by misoprostol 600 microg
Number of subjects: 480
Study: 11083885

Group type: EXPERIMENTAL
Intervention: SLTA patients
Number of subjects: 316

Group type: COMPARATOR
Intervention: Acute asthma patients (controls)
Number of subjects: 316
Study: 9044163

Group type: COMPARATOR
Intervention: etoposide phosphate
Number of subjects: 29
Study: 1417013

Group type: EXPERIMENTAL
Intervention: Ondansetron (4 mg intravenous injection)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo (saline injection)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Rescue medication (4 mg intravenous dose of ondansetron)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Side effects
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Total bilirubin elevation
Number of subjects: 63
Study: 2998181

Group type: EXPERIMENTAL
Intervention: Additional dietary fiber
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 30406840

Group type: EXPERIMENTAL
Intervention: Olaratumab plus doxorubicin
Number of subjects: 133
Study: 29763766

Group type: EXPERIMENTAL
Intervention: Healthy breakfast
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Unhealthy breakfast
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 36

Group type: COMPARATOR
Intervention: Quiet rest
Number of subjects: 36
Study: 27758945

Group type: EXPERIMENTAL
Intervention: Uric Acid (UA) 1000 mg
Number of subjects: 411

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 411
Study: 24732316

Group type: EXPERIMENTAL
Intervention: KRAS-variant
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: Wild-type alleles
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: Type 2 endometrial cancers
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: miRNA expression
Number of subjects: 467
Study: 22315480

Group type: EXPERIMENTAL
Intervention: Sulpiride
Number of subjects: 1324

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 1324

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 1324

Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 1324
Study: 20237484

Group type: EXPERIMENTAL
Intervention: Proparacaine eye drops (0.5%)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Second ROP screening (regardless of type of drops used)
Number of subjects: 40
Study: 18188581

Group type: EXPERIMENTAL
Intervention: Creatine (CR) supplementation (approximately 10 g day(-1) over 3 months)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (PL) (dextrose)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Creatine (CR) supplementation
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 18
Study: 16822133

Group type: EXPERIMENTAL
Intervention: Binding of visual features (shape-color combinations)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Learning of feature-conjunction probabilities
Number of subjects: 0
Study: 12719441

Group type: EXPERIMENTAL
Intervention: Perindopril (2 to 4 mg, n=28)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Telmisartan (80 to 160 mg, n=29)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Nifedipine GITS (30 to 60 mg, n=28)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Amlodipine (5 to 10 mg, n=28)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Atenolol (50 to 100 mg, n=29)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Nebivolol (5 to 10 mg, n=28)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Control group (40 healthy subjects)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (25 microg/s)
Number of subjects: 168
Study: 10818412

Group type: EXPERIMENTAL
Intervention: Cyproterone acetate (CA) COC (2 mg CA + 0.035 mg ethinylestradiol)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Desogestrel (D) COC (0.150 mg D + 0.030 mg ethinylestradiol)
Number of subjects: 24
Study: 8804868

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg each morning and clarithromycin 500 mg three times daily for 2 weeks
Number of subjects: 44

Group type: COMPARATOR
Intervention: Famotidine 40 mg twice daily and clarithromycin 500 mg three times daily for 2 weeks
Number of subjects: 44
Study: 1611221

Group type: EXPERIMENTAL
Intervention: Calcium supplementation of 800 mg daily (as calcium lactate gluconate)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Load-bearing exercise four times a week plus a daily placebo tablet
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Calcium supplementation daily and load-bearing exercise four times a week
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo tablet daily
Number of subjects: 50
Study: 30303614

Group type: EXPERIMENTAL
Intervention: Low glycaemic index (GI) diet during pregnancy
Number of subjects: 370

Group type: COMPARATOR
Intervention: Control group (standard dietary advice)
Number of subjects: 370
Study: 27555316

Group type: EXPERIMENTAL
Intervention: Letrozole for 5 days
Number of subjects: 238

Group type: COMPARATOR
Intervention: Aspirin for 5 days
Number of subjects: 238
Study: 26069138

Group type: EXPERIMENTAL
Intervention: Right lateral and head elevated position (group HE)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Right lateral position (group L)
Number of subjects: 44
Study: 23166195

Group type: EXPERIMENTAL
Intervention: Insecticide-treated curtains (ITCs)
Number of subjects: 2037

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 2037
Study: 21169609

Group type: EXPERIMENTAL
Intervention: Group PF (popliteal + femoral)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Group P (popliteal)
Number of subjects: 50
Study: 21353445

Group type: EXPERIMENTAL
Intervention: Interim methadone (IM)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Standard methadone (SM)
Number of subjects: 230
Study: 17486348

Group type: EXPERIMENTAL
Intervention: High dose steroid treatment for optic nerve neuritis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Steroid treatment for traumatic optic neuropathy
Number of subjects: 0
Study: 16294137

Group type: EXPERIMENTAL
Intervention: Daily alendronate therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 12006325

Group type: EXPERIMENTAL
Intervention: Neutrophil CD64 expression in patients with active inflammatory disease
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Neutrophil CD64 expression in patients with systemic infection
Number of subjects: 96

Group type: COMPARATOR
Intervention: Neutrophil CD64 expression in control patients (osteoarthritis and fibromyalgia)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: CD64 expression on neutrophils to diagnose systemic infection
Number of subjects: 96
Study: 9710005

Group type: EXPERIMENTAL
Intervention: Campylobacter jejuni lipopolysaccharides (LPSs)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Normal control subjects or patients with uncomplicated Campylobacter diarrhea
Number of subjects: 7
Study: 7824142

Group type: EXPERIMENTAL
Intervention: Sentence processing measures (sentence‐picture matching, grammaticality judgments, sentence completion)
Number of subjects: 0
Study: 2228714

Group type: EXPERIMENTAL
Intervention: PaperChase (self‐service computerized literature search)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Conventional resources (manually self‐performed searches and computerized MEDLINE searches by hospital librarians)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: PaperChase
Number of subjects: 57
Study: 641312

Group type: EXPERIMENTAL
Intervention: Methylergobasine and ergotamine tartrate
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 30
Study: 31318038

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine at a dose of 2 mcg/kg (max 100 mcg)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Oral midazolam at a dose of 0.5 mg/kg (max 15 mg)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine
Number of subjects: 75

Group type: COMPARATOR
Intervention: Oral midazolam
Number of subjects: 75
Study: 28715495

Group type: EXPERIMENTAL
Intervention: Text-based scenario training
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Picture-word imagery training
Number of subjects: 119

Group type: COMPARATOR
Intervention: Neutral control training
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: All training paradigms
Number of subjects: 119
Study: 26169803

Group type: EXPERIMENTAL
Intervention: Group Medical Visits (GMVs)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Individual visits (Standard Care)
Number of subjects: 128
Study: 23531280

Group type: EXPERIMENTAL
Intervention: Selenium supplementation (as sodium selenite) per os on the days of RT
Number of subjects: 81
Study: 21920001

Group type: EXPERIMENTAL
Intervention: Ramosetron 5μg once daily
Number of subjects: 343

Group type: COMPARATOR
Intervention: Mebeverine 135 mg three times daily
Number of subjects: 343
Study: 19369404

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) - target dosage 3 g/d
Number of subjects: 370

Group type: COMPARATOR
Intervention: Intravenous cyclophosphamide (IVC) - 0.5 to 1.0 g/m(2) in monthly pulses
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Both groups received prednisone, tapered from a maximum starting dosage of 60 mg/d
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Primary endpoint
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Secondary endpoints
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Deaths
Number of subjects: 370
Study: 16673804

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate 0.05% spray
Number of subjects: 27

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 27
Study: 15522039

Group type: EXPERIMENTAL
Intervention: Iontophoretic administration of acetylcholine (ACh)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Postocclusive reactive hyperaemia
Number of subjects: 39

Group type: COMPARATOR
Intervention: Brachial artery flow-mediated dilatation (FMD)
Number of subjects: 39
Study: 11284539

Group type: EXPERIMENTAL
Intervention: Chewing sugar-free gum (one piece chewed for 30 min 4 times per day)
Number of subjects: 11

Group type: COMPARATOR
Intervention: No gum chewing
Number of subjects: 11
Study: 9337490

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment for depression (CBT-D)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Relaxation training control (RTC)
Number of subjects: 35
Study: 8324641

Group type: EXPERIMENTAL
Intervention: Primary chemotherapy (cyclophosphamide, methotrexate, and 5-fluorouracil)
Number of subjects: 83
Study: 3526151

Group type: EXPERIMENTAL
Intervention: Diltiazem (90 mg every six hours)
Number of subjects: 576

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 576
Study: 29185022

Group type: EXPERIMENTAL
Intervention: Quetiapine ER (daily dose range 50 to 800 mg)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Aripiprazole (daily dose range 2.5 to 30 mg)
Number of subjects: 113
Study: 27294404

Group type: EXPERIMENTAL
Intervention: Elevated blood eosinophils at 4 weeks of life (≥ 5% of total leukocytes)
Number of subjects: 559

Group type: EXPERIMENTAL
Intervention: Blood eosinophil counts at 7 months of life (≥ 5%)
Number of subjects: 559

Group type: EXPERIMENTAL
Intervention: Blood eosinophils at 4.5% at 7 months of life
Number of subjects: 559
Study: 24072337

Group type: EXPERIMENTAL
Intervention: 5 mg/day rosuvastatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified treatment)
Number of subjects: 0
Study: 20970202

Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 20829157

Group type: EXPERIMENTAL
Intervention: Cold lateral compaction with 0.02 taper gutta‐percha cones and AH 26 sealer cement
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Cold lateral compaction with 0.02 taper Resilon cones and Epiphany sealer
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Single cone technique with 0.04 taper Resilon cones and Epiphany sealer
Number of subjects: 3
Study: 19055278

Group type: EXPERIMENTAL
Intervention: Acupuncture-medicine group (scalp electroacupuncture + Nimodipine)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Electroacupuncture group (scalp electroacupuncture)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Medication group (Nimodipine only)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Acupuncture-medicine group and Electroacupuncture group
Number of subjects: 270
Study: 16091876

Group type: EXPERIMENTAL
Intervention: Gammalinolenic acid (GLA) levels in eczema patients with elevated IgE (Group A, n = 15)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Gammalinolenic acid (GLA) levels in atopic controls (Group C, n = 8)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Gammalinolenic acid (GLA) levels in eczema patients with normal IgE (Group B, n = 7)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Gammalinolenic acid (GLA) levels in non-atopic controls (Group D, n = 6)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Correlation of total IgE levels with GLA
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Correlation of total IgE levels with arachidonic acid (AA)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Regression line slope for low-IgE responders (Groups B and D)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Regression line slope for high-IgE responders (Groups A and C)
Number of subjects: 22
Study: 12054324

Group type: EXPERIMENTAL
Intervention: Brief Supportive-Expressive Group Psychotherapy
Number of subjects: 133

Group type: COMPARATOR
Intervention: Standard medical care
Number of subjects: 133
Study: 9929747

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 7583550

Group type: EXPERIMENTAL
Intervention: Major locus with a codominant mixture model including sex, age, plasma concentrations of apoAI and triglycerides, exogenous sex hormone use, and menopausal status.
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: Inclusion of four covariates (sex, age, apoAI, triglycerides) in the model.
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: Linkage analyses with penetrance parameter estimates from segregation analysis.
Number of subjects: 526
Study: 2285001

Group type: EXPERIMENTAL
Intervention: Naftidrofuryl (oral formulation)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 7015820

Group type: EXPERIMENTAL
Intervention: Vitamin C supplements
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 94
Study: 29955161

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (48IU/day, n=53)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo (n=53)
Number of subjects: 106
Study: 29609133

Group type: EXPERIMENTAL
Intervention: Brief intervention on substance use
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Heavier smokers
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Intention to quit smoking
Number of subjects: 151
Study: 27102196

Group type: EXPERIMENTAL
Intervention: Community health interventions including training of community health workers and traditional birth attendants, establishment of community health clubs, and mobile clinic services.
Number of subjects: 13423

Group type: COMPARATOR
Intervention: Usual services provided to the control group.
Number of subjects: 13423
Study: 25399620

Group type: EXPERIMENTAL
Intervention: Fillerina®
Number of subjects: 40
Study: 21914717

Group type: EXPERIMENTAL
Intervention: LED phototherapy
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conventional fluorescent blue light
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conventional halogen light
Number of subjects: 45
Study: 20299958

Group type: EXPERIMENTAL
Intervention: Isoniazid preventive therapy (IPT)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control clusters (minimal IPT use)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Laboratory substudy
Number of subjects: 126
Study: 18612574

Group type: EXPERIMENTAL
Intervention: Interactive Voice Response (IVR) for alcohol-related problems (n = 562)
Number of subjects: 1684

Group type: EXPERIMENTAL
Intervention: Interactive Voice Response (IVR) for physical/sexual abuse and sexual orientation (n = 563)
Number of subjects: 1684

Group type: EXPERIMENTAL
Intervention: Interactive Voice Response (IVR) for respondents aged 18-39 (n = 563)
Number of subjects: 1684

Group type: COMPARATOR
Intervention: Control group (n = 559)
Number of subjects: 1684
Study: 16076741

Group type: EXPERIMENTAL
Intervention: Ontology display with history representation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Compatibility between types of ontology display and history representation
Number of subjects: 30
Study: 12397049

Group type: COMPARATOR
Intervention: Systolic Blood Pressure (BP)
Number of subjects: 2181

Group type: COMPARATOR
Intervention: Diastolic Blood Pressure (BP)
Number of subjects: 2181

Group type: COMPARATOR
Intervention: Pulse Pressure
Number of subjects: 2181

Group type: COMPARATOR
Intervention: Mean Arterial Pressure
Number of subjects: 2181
Study: 10572081

Group type: EXPERIMENTAL
Intervention: PEG‐rHuMGDF (2.5 microg/kg/d or 5 microg/kg/d for up to 21 doses)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: PEG‐rHuMGDF (2.5 microg/kg, single dose) and 7 daily doses of 2.5 microg/kg
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: PEG‐rHuMGDF (group A)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: PEG‐rHuMGDF (group B)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: PEG‐rHuMGDF
Number of subjects: 108
Study: 8649492

Group type: EXPERIMENTAL
Intervention: Artemether
Number of subjects: 576

Group type: COMPARATOR
Intervention: Quinine
Number of subjects: 576
Study: 1804861

Group type: EXPERIMENTAL
Intervention: Cardiac catheterization
Number of subjects: 20
Study: 6558295

Group type: EXPERIMENTAL
Intervention: Self-care instruction program adapted from the Health PACT program
Number of subjects: 42

Group type: COMPARATOR
Intervention: Health discussion (Control group)
Number of subjects: 42
Study: 30191779

Group type: EXPERIMENTAL
Intervention: Mamma Mia (internet-based intervention)
Number of subjects: 1342

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1342
Study: 30403270

Group type: EXPERIMENTAL
Intervention: Lifestyle interventions including four educational sessions on strategies for lowering blood sugar, increasing physical activity, promoting weight loss, prudent diet, and foot caring, followed for 12 weeks.
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 74
Study: 26959810

Group type: EXPERIMENTAL
Intervention: Atorvastatin treatment group
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Non-treatment mTBI group
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (orthopedic injury)
Number of subjects: 75
Study: 24909836

Group type: EXPERIMENTAL
Intervention: Postnatal psychoeducation programme
Number of subjects: 114

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 114
Study: 22300780

Group type: EXPERIMENTAL
Intervention: Protocol A (30 seconds interval, passive recovery)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Protocol B (30 seconds interval, active recovery)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Protocol C (90 seconds interval, passive recovery)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Protocol D (90 seconds interval, active recovery)
Number of subjects: 20
Study: 20334688

Group type: EXPERIMENTAL
Intervention: OAKP (Osteoarthritis Knee Program)
Number of subjects: 146

Group type: COMPARATOR
Intervention: ASMP (Arthritis Self-Management Program)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: OAKP and ASMP
Number of subjects: 146
Study: 18560642

Group type: EXPERIMENTAL
Intervention: Combined composite-amalgam restoration (ADAC, ADACM)
Number of subjects: 48

Group type: COMPARATOR
Intervention: All amalgam restoration (AM)
Number of subjects: 48

Group type: COMPARATOR
Intervention: All amalgam plus dentin adhesive (ADA)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Amalgam plus dentin adhesive plus composite resin (ADAC)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Amalgam plus dentin adhesive plus composite resin with modified preparation design (ADACM)
Number of subjects: 48
Study: 15866966

Group type: EXPERIMENTAL
Intervention: Printed manual instruction
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Video instruction
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Hands-on instruction
Number of subjects: 93

Group type: COMPARATOR
Intervention: All training groups
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: All groups after instruction
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: All groups before instruction
Number of subjects: 93
Study: 12456943

Group type: COMPARATOR
Intervention: Control children (133 patients)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Children with CHF (31 patients)
Number of subjects: 164
Study: 10325274

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided embryo transfer
Number of subjects: 187

Group type: COMPARATOR
Intervention: Clinical touch embryo transfer
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided embryo transfer in older women (>=37 years old)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided embryo transfer in difficult procedures
Number of subjects: 187

Group type: COMPARATOR
Intervention: Clinical touch embryo transfer in difficult procedures
Number of subjects: 187